Gagyor Ildiko, Madhok Vishnu B, Daly Fergus, Sullivan Frank
Department of General Practice, Universitätsklinikum Würzburg, Josef-Schneider-Straße 2, Würzburg, Bavaria, Germany, 97080.
Cochrane Database Syst Rev. 2019 Sep 5;9(9):CD001869. doi: 10.1002/14651858.CD001869.pub9.
Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. This review was first published in 2001 and most recently updated in 2015. Since a significant benefit of corticosteroids for the early management of Bell's palsy has been demonstrated, the main focus of this update, as in the previous version, was to determine the effect of adding antivirals to corticosteroid treatment. We undertook this update to integrate additional evidence and to better assess the robustness of findings, taking risk of bias fully into account.
To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy.
We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS in July 2019. We reviewed the bibliographies of the identified trials and contacted trial authors to identify additional published or unpublished data. We searched clinical trials registries for ongoing studies.
We considered randomised controlled trials (RCTs) or quasi-RCTs of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy. We excluded trials that followed-up participants for less than three months.
We independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures. We performed sensitivity analyses excluding trials at high or unclear risk of bias in at least five domains, and reported these data as the primary analyses.
Fourteen trials, including 2488 participants, met the inclusion criteria. Most were small, and most were at high or unclear risk of bias in multiple domains. We included four new studies at this update.Incomplete recoveryA combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in people with Bell's palsy compared to corticosteroids alone (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.38 to 1.74; 3 trials, N = 766; random-effects; low-certainty evidence). We excluded 10 trials that were at high or unclear risk of bias in several domains from this analysis and limited all analyses to studies at lower risk of bias. Recovery rates were better in participants receiving corticosteroids alone than antivirals alone (RR 2.69, 95% CI 0.73 to 10.01; 2 trials, N = 667; random-effects), but the result was imprecise and allowed for the possibility of no effect. The rate of incomplete recovery was lower with antivirals plus corticosteroids than with placebo or no treatment (RR 0.56, 95% CI 0.42 to 0.76; 2 trials, N = 658; random-effects). Antivirals alone had no clear effect on incomplete recovery rates compared with placebo, but the result was imprecise (RR 1.10, 95% CI 0.87 to 1.40; 2 trials, N = 658; fixed-effect). For people with severe Bell's palsy (House-Brackmann score of 5 and 6, or equivalent on other scales), we found that the combination of antivirals and corticosteroids had no clear effect on incomplete recovery at month six compared to corticosteroids alone, although the result was again imprecise (RR 0.82, 95% CI 0.57 to 1.17; 2 trials, N = 98; random-effects).Motor synkinesis or crocodile tearsAntivirals plus corticosteroids reduced the proportion of participants who experienced these long-term sequelae from Bell's palsy compared to placebo plus corticosteroids (RR 0.56, 95% CI 0.36 to 0.87; 2 trials, N = 469; fixed-effect; moderate-certainty evidence). Antivirals plus corticosteroids reduced long-term sequelae compared to placebo but there was no clear difference in this outcome with antivirals alone compared to placebo.Adverse events Adverse event data were available in four studies providing data on 1592 participants. None of the four comparisons showed clear differences in adverse events between treatment and comparison arms (very low-certainty evidence); for the comparison of antivirals plus corticosteroids and corticosteroids alone in studies at lower risk of bias, the RR was 1.17 (95% CI 0.81 to 1.69; 2 trials, N = 656; fixed-effect; very low-certainty evidence).
AUTHORS' CONCLUSIONS: The combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in comparison to corticosteroids alone in Bell's palsy of various degrees of severity, or in people with severe Bell's palsy, but the results were very imprecise. Corticosteroids alone were probably more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no clear benefit from antivirals alone over placebo.The combination of antivirals and corticosteroids probably reduced the late sequelae of Bell's palsy compared with corticosteroids alone. Studies also showed fewer episodes of long-term sequelae in corticosteroid-treated participants than antiviral-treated participants.We found no clear difference in adverse events from the use of antivirals compared with either placebo or corticosteroids, but the evidence is too uncertain for us to draw conclusions.An adequately powered RCT in people with Bell's palsy that compares different antiviral agents may be indicated.
皮质类固醇广泛用于治疗特发性面神经麻痹(贝尔麻痹),但联合使用抗病毒药物的有效性尚不确定。本综述首次发表于2001年,最近一次更新于2015年。由于已证明皮质类固醇对贝尔麻痹的早期治疗有显著益处,本次更新的主要重点,与上一版一样,是确定在皮质类固醇治疗中添加抗病毒药物的效果。我们进行本次更新是为了整合更多证据,并在充分考虑偏倚风险的情况下,更好地评估研究结果的稳健性。
评估单独使用抗病毒治疗或与其他任何疗法联合用于贝尔麻痹的效果。
我们于2019年7月检索了Cochrane神经肌肉专业注册库、CENTRAL、MEDLINE、Embase和LILACS。我们查阅了已识别试验的参考文献,并联系试验作者以识别其他已发表或未发表的数据。我们检索临床试验注册库以查找正在进行的研究。
我们纳入了将使用和不使用皮质类固醇的抗病毒药物与对照疗法进行比较以治疗贝尔麻痹的随机对照试验(RCT)或半随机对照试验。我们排除了随访参与者少于三个月的试验。
我们使用Cochrane标准程序独立评估试验的相关性、纳入标准和偏倚风险。我们进行了敏感性分析,排除了至少五个领域偏倚风险高或不明确的试验,并将这些数据作为主要分析结果报告。
14项试验,包括2488名参与者,符合纳入标准。大多数试验规模较小,且在多个领域偏倚风险高或不明确。本次更新纳入了四项新研究。
不完全恢复
与单独使用皮质类固醇相比,抗病毒药物与皮质类固醇联合使用对贝尔麻痹患者不完全恢复率可能几乎没有影响或无影响(风险比(RR)0.81,95%置信区间(CI)0.38至1.74;3项试验,N = 766;随机效应;低确定性证据)。我们在本次分析中排除了10项在多个领域偏倚风险高或不明确的试验,并将所有分析限制在偏倚风险较低的研究中。单独接受皮质类固醇治疗的参与者的恢复率优于单独接受抗病毒药物治疗的参与者(RR 2.69,95% CI 0.73至10.01;2项试验,N = 667;随机效应),但结果不精确,且可能无效果。与安慰剂或不治疗相比,抗病毒药物加皮质类固醇的不完全恢复率更低(RR 0.56,95% CI 0.42至0.76;2项试验,N = 658;随机效应)。与安慰剂相比,单独使用抗病毒药物对不完全恢复率没有明确影响,但结果不精确(RR 1.10,95% CI 0.87至1.40;2项试验,N = 658;固定效应)。对于重度贝尔麻痹患者(House - Brackmann评分为5和6,或其他量表上的等效评分),我们发现与单独使用皮质类固醇相比,抗病毒药物与皮质类固醇联合使用在第6个月时对不完全恢复没有明确影响,尽管结果同样不精确(RR 0.82,95% CI 0.57至1.17;2项试验,N = 98;随机效应)。
运动联带运动或鳄鱼泪
与安慰剂加皮质类固醇相比,抗病毒药物加皮质类固醇可降低贝尔麻痹患者出现这些长期后遗症的参与者比例(RR 0.56,95% CI 0.36至0.87;2项试验,N = 469;固定效应;中度确定性证据)。与安慰剂相比,抗病毒药物加皮质类固醇可减少长期后遗症,但单独使用抗病毒药物与安慰剂相比,此结果无明显差异。
不良事件
四项研究提供了1592名参与者的不良事件数据。四项比较中均未显示治疗组和对照组之间在不良事件方面有明显差异(极低确定性证据);对于偏倚风险较低的研究中抗病毒药物加皮质类固醇与单独使用皮质类固醇的比较,RR为1.17(95% CI 0.81至1.69;2项试验,N = 656;固定效应;极低确定性证据)。
在不同严重程度的贝尔麻痹患者或重度贝尔麻痹患者中,与单独使用皮质类固醇相比,抗病毒药物与皮质类固醇联合使用对不完全恢复率可能几乎没有影响或无影响,但结果非常不精确。单独使用皮质类固醇可能比单独使用抗病毒药物更有效,且抗病毒药物加皮质类固醇比安慰剂或不治疗更有效。单独使用抗病毒药物与安慰剂相比没有明显益处。与单独使用皮质类固醇相比,抗病毒药物与皮质类固醇联合使用可能减少了贝尔麻痹的晚期后遗症。研究还表明,接受皮质类固醇治疗的参与者长期后遗症发作次数少于接受抗病毒药物治疗的参与者。我们发现与安慰剂或皮质类固醇相比,使用抗病毒药物的不良事件没有明显差异,但证据过于不确定,我们无法得出结论。可能需要进行一项针对贝尔麻痹患者的有足够样本量的RCT,比较不同的抗病毒药物。